Depressing drug result for Astra
8th Nov 2011 07:40
An anti-depressant product made by Anglo-Swedish drugs titan AstraZeneca and US partner Targacept has failed to meet its initial target. The product, known as as TC-5214, is intended to be used as an adjunct therapy to an anti-depressant in patients with major depressive disorder (MDD), who do not
Read moreFriday tips round-up: Astra, Croda, Clinton Cards...
28th Oct 2011 06:52
AstraZeneca faces an upcoming threat in the form of generic copies of Pfizer's Lipitor cholesterol treatment in the US, notes the Investment Column in the Independent. This will present a challenge for Astra's Crestor cholesterol drug, which has been selling well. Yesterday's results showed its sale
Read moreLondon close: Big gains on Euro hopes
27th Oct 2011 16:43
Stocks posted big gains amid optimism following the agreements reached on the Eurozone situation last night. Banks in particular are on the attack, with Barclays and RBS posting double-digit gains. EUROZONE AGREEMENT BOOSTS THE MARKETS Working into the early hours of the morning, Eurozone official
Read moreLondon midday: Double-digit gains for Barclays, RBS
27th Oct 2011 12:04
Stocks are posting big gains amid optimism following the agreements reached on the Eurozone situation last night. Banks in particular are on the attack, with Barclays and RBS posting double-digit gains. EUROZONE AGREEMENT BOOSTS THE MARKETS Working into the early hours of the morning, Eurozone off
Read moreUPDATE: Thursday broker round-up
27th Oct 2011 09:09
Smith&Nephew: Citi reiterates sell. Anglo American: Citi maintains at buy. Invensys: UBS raises to neutral-short term buy from neutral. Lowers target to 225p from 250p. Bellway: UBS keeps at buy, raises target price to 825p from 793p. Lloyds: Credit Suisse cuts target to 31p from 40p, keeps at
Read moreLondon open: Markets celebrate euro agreements
27th Oct 2011 08:30
Just one stock was in the red on the FTSE 100 in the opening minutes of Thursday, as markets turned bullish on the back of a three-prongued deal in the Eurozone last night. The blue chip index in London jumped 1.85% early on, joining all major benchmarks across the continent this morning, with indic
Read moreAstraZeneca sees revenues down in Q3 -UPDATE
27th Oct 2011 07:21
AstraZeneca, the FTSE 100 pharmaceuticals giant, has seen revenues fall 2% at constant exchange rates to $8,213m (Consensus: $8,187m) in the third quarter compared to the same period of 2010. On the back of these revenues, core operating profit was also down 2% at $3,177m (Consensus: $3,099m), with
Read moreLondon pre-open: Triple digit rise for Footsie expected
27th Oct 2011 07:20
The market is set to give the thumbs-up to the measures announced by European leaders last night, which included bumping up the region's bail-out fund to €1trn and an agreement with Greek bond-holders that they should take a 50% 'haircut' on the value of the bonds. The response to the announcement
Read moreThursday preview: Shell, Astra, Bloomsbury
26th Oct 2011 15:49
Results from Royal Dutch Shell will, as usual, be compared to those from BP. Charles Stanley's Tony Shepard thinks the comparison will be favourable. "Shell could report a 29% rise in Q3 [third quarter] earnings to $6.3bn which, on the face of it, will be more positive than other groups such as BP
Read moreUPDATE: First broker tip round-up of the morning
30th Sep 2011 08:48
Intertek: UBS downgrades to ´sell´ from ´neutral´, cuts target to 1750p from 2000p. Tate&Lyle: UBS keeps at ´neutral´, raises target to 615p from 595p. Carphone: Alpha Value upgrades to 'add' from 'reduce'. IMI: Alpha Value upgrades to 'buy' from 'add'. Astra Zenaca: Seymour Pierce stays at 'r
Read moreLondon open: AstraZeneca the sole FTSE 100 riser
30th Sep 2011 08:26
Stocks have continued their downward turn amid ongoing uncertainty over the Eurozone situation. Data showing consumer confidence has risen for the first time in four months has failed to lighten the mood. The index of sentiment remained firmly negative in September at -30, up a point from the pre
Read moreAstra settles Seroquel dispute with Handa
30th Sep 2011 08:02
Drugs giant AstraZeneca has come to an accommodation with generic drugs rival Handa Pharmaceuticals over their legal dispute regarding Astra's Seroquel XR drug. The agreement settles the patent infringement litigation filed by AstraZeneca following Handa's submission to the US Food and Drug Adminis
Read moreLondon pre-open: Modest falls expected
30th Sep 2011 07:55
There is little sign of London pulling out of its slide, with City sources predicting the FTSE 100 will open down 38 points from yesterday's close of 5,197. Drugs giant AstraZeneca has entered into a settlement agreement in its US SEROQUEL XR patent infringement litigation against Handa Pharmaceuti
Read moreLondon close: Footsie tumbles over 2%
2nd Sep 2011 16:30
The Footsie finished over 2% down on Friday, as London was not immune from the global sell-off, meaning that just eight out of the 100 blue chips stocks closed in the blue. After a poor start in early trade, sentiment was dampened after a worse-than-expected jobs report in the US which showed that n
Read moreLondon midday: Stocks stuck lower ahead of jobs data
2nd Sep 2011 12:27
London's leading share index is firmly in the red now, giving up gains from earlier this week ahead of the big US jobs report due this afternoon. The eagerly awaited headline results from a clinical trial comparing AstraZeneca's cholesterol treatment Crestor to Pfizer's Lipitor have been released,
Read more